Opioid Use Disorder
Conditions
Keywords
Opioid Use Disorder
Brief summary
The goal of this pilot study is to evaluate the feasibility and acceptability of implementing a peer recovery support program to support patient engagement in medication treatment for opioid use disorder (MOUD). The program, entitled "Promoting Enhanced Engagement through Recovery Support" (PEERS) was developed in collaboration with community and clinical partners for the MOUD outpatient setting. Information gathered during this pilot study will inform refinements to the program and study components for a future clinical trial that will evaluate the effectiveness of the peer recovery support program in increasing patient retention in MOUD. The investigators will recruit 12 participants to the pilot study, all of whom will receive the PEERS program. The study will take place in Geisinger outpatient addiction treatment clinics in northeast Pennsylvania. Patients initiating MOUD treatment at one of the clinics will be eligible for participation, and will be recruited via email, patient portal messages, and phone. Each participant will receive the PEERS program, entailing regular sessions with a Certified Recovery Specialist (CRS) for 6 months. Participants will also be asked to complete assessments at baseline and 12 weeks and will be invited to provide qualitative feedback on their experience with the program through an interview conducted between 8-12 weeks. As the focus of the pilot pertains to the feasibility and acceptability of the program and the study components, study outcomes focus on participant engagement in and acceptance of the program, CRS fidelity to the program, barriers to implementation, and feasibility of data collection.
Interventions
BEHAVIORALPRS Program
The Peer Recovery Support program will be delivered by a certified recovery specialist (CRS) over the course of 6-months. The CRS will provide supportive care to the participant during their initial 6-months of MOUD treatment to increase patient engagement in their treatment. The CRS may provide emotional support; help participants to identify their recovery assets, goals, and barriers; guide participants in creating a recovery plan; help participants to increase their coping skills; and assist participants in connecting to community and recovery resources.
Sponsors
Geisinger Clinic
National Institute on Drug Abuse (NIDA)
UConn Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
* Adult ≥ 18 years of age * Initiated medication for opioid use disorder at a Geisinger outpatient addiction treatment clinic within the past 45 days * Willing to participate in the Peer Recovery Support program * Able and willing to provide consent
Exclusion criteria
* Received medication for opioid use disorder at a Geisinger outpatient addiction treatment clinic in the 90 days prior to the treatment initiation date * Not proficient in English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility - Participant Engagement in the Peer Recovery Support Program | Baseline to 12 weeks | Percent of participants who attended at least 2 sessions with the Certified Recovery Specialist |
| Acceptability - Participant Alliance With Certified Recovery Specialist | 12 weeks | Participants' average scores for the Scales for Participant Alliance with Recovery Coach (SPARC-2); score can range from 1-5 and a high score indicates greater satisfaction with the CRS. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility - Feasibility of Assessment Completion | Baseline | Percent of participants who completed the baseline assessment |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMelissa Poulsen, PhD
Geisinger Clinic
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 13 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 12 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 13 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 13 |
Outcome results
None listed